Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Single-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy and safety study using the Allergen BioCube (ABC).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: 3E Therapeutics Corporation
• Collaborator: ORA, Inc.
• Treatments: Pharmaceutical Solutions

Criteria

Key Inclusion Criteria:

• Must be 18 years of age and provide written informed consent and sign the HIPAA form

• Must have history of allergic rhinitis

• Must have positive response to Allergen BioCube

Key Exclusion Criteria:

• Must not have a significant illness such as moderate to severe allergic asthmatic reactions

• Must not have compromised lung function

• Must not use any disallowed medications

• Must not have been in an investigational study in the last 30 days